Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Unfathomable and Entertaining Legal disputes That Surprise everyone - 2An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- 321 Incredibly Entertaining Contemplations To Observe Consistently
- 4Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- 5The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
- Israeli media reports Iran attacking greater Tel Aviv region
- The most effective method to Oversee Unsold SUVs in the Car Business
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
- Vote in favor of your #1 sort of juice
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- The most effective method to Pick the Right Teeth Substitution Choice for You
